Metastatic tumours to the eye. Review of metastasis to the iris, ciliary body, choroid, retina, optic disc, vitreous, and/or lens capsule.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
20
09
2021
accepted:
28
02
2022
revised:
31
01
2022
pmc-release:
01
04
2024
medline:
30
3
2023
pubmed:
21
3
2022
entrez:
20
3
2022
Statut:
ppublish
Résumé
Metastasis to the eye can involve the choroid (90%), ciliary body (2%), iris (8%), and retina, optic disc, vitreous, and/or lens capsule (<1-4%). The mean number of uveal metastasis per eye (1.7), mean tumour base (11.6 mm) and thickness (3.2 mm), tumour colour (86% yellow), and presence of subretinal fluid (72%), are all clinical features suggestive of the diagnosis. Imaging with ultrasonography demonstrates an echodense mass (80%) and optical coherence tomography shows a "lumpy bumpy" choroidal surface (64%), both important diagnostic features. Uveal metastases typically emanate from primary cancer of the breast (37%), lung (27%), kidney (4%), gastrointestinal tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), and other sites (3%). Occasionally, fine needle aspiration biopsy is employed if the primary site is not known. In 16% of cases, the primary site remains unknown. Rarely, metastases affect the retina, vitreous, and lens capsule, most often originating from cutaneous melanoma and in patients previously treated with checkpoint inhibitor therapy. Kaplan-Meier analysis in a series of 1111 patients with uveal metastasis revealed 32% survival at 3 years and 24% at 5 years. Patients with uveal metastasis from carcinoid tumour showed most favourable survival at 5-years (92%), whereas pancreatic and kidney cancer demonstrated least favourable survival (0%). The 5-year survival was better for females (versus (vs.) males) (31% vs. 21%) and older adults (vs. children) (40% vs. 0%). In this review, we examine several large-cohort publications on the topic of ocular metastasis. 摘要: 肿瘤可以转移至眼的脉络膜(90%), 睫状体(2%), 虹膜(8%)和视网膜, 视盘, 玻璃体和/或晶状体囊(<1–4%)等部位。每只眼脉络膜转移的平均数量为1.7, 平均肿瘤基底部的宽度为11.6 mm, 厚度为3.2 mm, 肿瘤颜色(86%黄色), 视网膜下积液(72%)这些临床特征都是诊断依据。超声成像提示有回声肿块(80%), 光学相干断层扫描(OCT)提示脉络膜表面有“块状隆起” (64%), 为重要的诊断特征。葡萄膜的转移性肿瘤通常来源于乳腺(37%), 肺(27%), 肾(4%), 胃肠道(4%), 皮肤黑色素瘤(2%), 肺类癌(2%), 前列腺(2%), 甲状腺(1%), 胰腺(1%)和其他部位(3%)。少数原发部位未明的眼部转移肿瘤可采用细针穿刺进行活检。在16%的病例中, 转移肿瘤的原发部位仍然未知。在极少数情况下, 转移肿瘤会侵犯视网膜, 玻璃体, 晶状体囊, 这些肿瘤多数来源于皮肤黑色素瘤和既往使用免疫检查点抑制剂治疗过的病人。对1111名有葡萄膜转移肿瘤的病人使用Kaplan-Meier生存分析, 结果提示3年生存率为32%, 5年生存率为24%。其中, 类癌葡萄膜转移的病人5年生存率最高(92%),而前列腺和肾脏来源的葡萄膜肿瘤生存率最低(0%)。女性(vs.男性)(31% vs.21%)和老年人(vs.儿童)(40% vs.0%)的5年生存率更好。在这篇综述中, 我们验证了一些以眼部转移肿瘤为主题的大型队列研究的成果。.
Autres résumés
Type: Publisher
(chi)
摘要: 肿瘤可以转移至眼的脉络膜(90%), 睫状体(2%), 虹膜(8%)和视网膜, 视盘, 玻璃体和/或晶状体囊(<1–4%)等部位。每只眼脉络膜转移的平均数量为1.7, 平均肿瘤基底部的宽度为11.6 mm, 厚度为3.2 mm, 肿瘤颜色(86%黄色), 视网膜下积液(72%)这些临床特征都是诊断依据。超声成像提示有回声肿块(80%), 光学相干断层扫描(OCT)提示脉络膜表面有“块状隆起” (64%), 为重要的诊断特征。葡萄膜的转移性肿瘤通常来源于乳腺(37%), 肺(27%), 肾(4%), 胃肠道(4%), 皮肤黑色素瘤(2%), 肺类癌(2%), 前列腺(2%), 甲状腺(1%), 胰腺(1%)和其他部位(3%)。少数原发部位未明的眼部转移肿瘤可采用细针穿刺进行活检。在16%的病例中, 转移肿瘤的原发部位仍然未知。在极少数情况下, 转移肿瘤会侵犯视网膜, 玻璃体, 晶状体囊, 这些肿瘤多数来源于皮肤黑色素瘤和既往使用免疫检查点抑制剂治疗过的病人。对1111名有葡萄膜转移肿瘤的病人使用Kaplan-Meier生存分析, 结果提示3年生存率为32%, 5年生存率为24%。其中, 类癌葡萄膜转移的病人5年生存率最高(92%),而前列腺和肾脏来源的葡萄膜肿瘤生存率最低(0%)。女性(vs.男性)(31% vs.21%)和老年人(vs.儿童)(40% vs.0%)的5年生存率更好。在这篇综述中, 我们验证了一些以眼部转移肿瘤为主题的大型队列研究的成果。.
Identifiants
pubmed: 35306540
doi: 10.1038/s41433-022-02015-4
pii: 10.1038/s41433-022-02015-4
pmc: PMC10050009
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-814Informations de copyright
© 2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Cohen VML. Ocular metastases. Eye. 2013;27:137–41.
pubmed: 23222564
doi: 10.1038/eye.2012.252
Shields JA, Shields CL. Metastatic tumors to the uvea retina and optic disc. In: Shields JA, Shields CL, editors. Intraocular tumors. an atlas and textbook. 3rd ed. Philadelphia, PA: Lippincott Wolters Kluwers; 2016, pp. 213–45.
Shields CL, Welch RJ, Malik K, Acaba-Berrocal LA, Selzer EB, Newman JH, et al. Uveal metastasis: clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin. Middle East Afr J Ophthalmol. 2018;25:81–90.
pubmed: 30122853
pmcid: 6071342
doi: 10.4103/meajo.MEAJO_6_18
Konstantinidis L, Damato B. Intraocular metastases–a review. Asia Pac J Ophthalmol. 2017;6:208–14.
Arepalli S, Kaliki S, Shields CL. Choroidal metastases: origin, features, and therapy. Indian J Ophthalmol. 2015;63:122–7.
pubmed: 25827542
pmcid: 4399120
doi: 10.4103/0301-4738.154380
Shields CL, Shields JA, Gross NE, Schwartz G, Lally S. Survey of 520 eyes with uveal metastases. Ophthalmology. 1997;104:1265–76.
pubmed: 9261313
doi: 10.1016/S0161-6420(97)30148-1
Stephens RF, Shields JA. Diagnosis and management of cancer metastatic to the uvea. A study of 70 cases. Ophthalmology. 1979;86:1336–49.
pubmed: 233866
doi: 10.1016/S0161-6420(79)35393-3
Duke-Elder S. System of ophthalmology, vol 9: Diseases of the uveal tract. St Louis: CV Mosby; 1966, 917.
Hart WM. Metastatic carcinoma to the eye and orbit. Int Ophthalmol Clin. 1962;212:465–82.
doi: 10.1097/00004397-196206000-00012
Albert DM, Rubenstein RA, Scheie HG. Tumors metastasis to the eye. I. Incidence in 213 adult patients with generalized malignancy. Am J Ophthalmol. 1967;63:723–726.
pubmed: 6022244
doi: 10.1016/0002-9394(67)91297-4
Jensen OA. Metastatic tumors of the eye and orbit. A histopathological analysis of a Danish series. Acta Pathol Microbiol Scand. 1970;212:201–14. (suppl)
Bloch RS, Gartner S. The incidence of ocular metastatic carcinoma. Arch Ophthalmol. 1971;85:673–5.
pubmed: 5562786
doi: 10.1001/archopht.1971.00990050675005
Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. I. A clinicopathologic study of 227 cases. Arch Ophthalmol. 1974;92:276–86.
pubmed: 4412321
doi: 10.1001/archopht.1974.01010010286003
Eliassi-Rad B, Albert DM, Green WR. Frequency of ocular metastases in patients dying of cancer in eye bank populations. Br J Ophthalmol. 1996;80:125–8.
pubmed: 8814741
pmcid: 505402
doi: 10.1136/bjo.80.2.125
Nelson CC, Hertzberg BS, Klintworth GK. A histopathologic study of 716 unselected eyes in patients with cancer at the time of death. Am J Ophthalmol. 1983;95:788–93.
pubmed: 6859188
doi: 10.1016/0002-9394(83)90066-1
Shields CL, Acaba-Berrocal LA, Selzer EB, Mayro EL, Newman JH, Malik K, et al. Uveal metastasis based on patient age in 1,111 patients: Comparison of clinical features and outcomes per age category. Retina. 2020;40:204–13.
pubmed: 31972789
doi: 10.1097/IAE.0000000000002364
Welch RJ, Malik K, Considine SP, Acaba-Berrocal L, Selzer E, Newman J, et al. Uveal metastasis based on patient sex in 2214 tumors of 1111 patients. A comparison of female versus male clinical features and outcomes. Asia Pac J Ophthalmol. 2019;8:298–303.
doi: 10.1097/APO.0000000000000247
Welch RJ, Malik K, Mayro EL, Newman J, Honig S, Ang SM, et al. Uveal metastasis in 1111 patients: Interval to metastasis and overall survival based on timing of primary cancer diagnosis. Saudi J Ophthalmol. 2019;33:229–37.
pubmed: 31686963
pmcid: 6819751
doi: 10.1016/j.sjopt.2019.07.006
Freedman M, Folk JC. Metastatic tumors to the eye and orbit patient survival and clinical characteristics. Arch Ophthalmol. 1987;105:1215–1219.
pubmed: 3307718
doi: 10.1001/archopht.1987.01060090073031
Demirci H, Shields CL, Chao AN, Shields JA. Uveal metastasis from breast cancer in 264 patients. Am J Ophthalmol. 2003;136:264–71.
pubmed: 12888048
doi: 10.1016/S0002-9394(03)00192-2
Shah SU, Mashayekhi A, Shields CL, Walia HS, Hubbard GB, Zhang J, et al. Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients. Ophthalmology. 2014;121:252–7.
doi: 10.1016/j.ophtha.2013.07.014
Shah SU, Shields CL, Bianciotto CG, Shields JA. Pancreatic cancer metastasis to choroid. Ophthalmology 2011;118:1483.
pubmed: 21724049
doi: 10.1016/j.ophtha.2011.02.004
de Bustros S, Augsburger JJ, Shields JA, Shakin EP, Pryor CC. Intraocular metastases from cutaneous malignant melanoma. Arch Ophthalmol. 1985;103:937–40.
pubmed: 4015484
doi: 10.1001/archopht.1985.01050070063031
Zografos L, Mirimanoff RO, Angeletti CA, Frosini R, Beati D, Schalenbourg A, et al. Systemic melanoma metastatic to the retina and vitreous. Ophthalmologica. 2004;218:424–33.
pubmed: 15564763
doi: 10.1159/000080948
Harbour JW, De Potter P, Shields CL, Shields JA. Uveal metastasis from carcinoid tumor. Clinical observations in nine cases. Ophthalmology. 1994;101:1084–90.
pubmed: 8008351
doi: 10.1016/S0161-6420(94)38030-4
Masoomian B, Mashayekhi A, Shields JA, Shields CL. Uveal melanoma metastasis to the contralateral eye structures: a retrospective comparative analysis of 13 consecutive patients. Ophthalmol Retina. 2021;5:1036–42. https://doi.org/10.1016/j.oret.2020.12.025 .
Shields CL, Pellegrini M, Ferenczy SR, Shields JA. Enhanced depth imaging optical coherence tomography (EDI-OCT) of intraocular tumors. From placid to seasick to rock and rolling topography. The 2013 Francesco Orzalesi Lecture. Retina. 2014;34:1495–512.
pubmed: 25014847
doi: 10.1097/IAE.0000000000000288
Al-Dahmash SA, Shields CL, Kaliki S, Johnson T, Shields JA. Enhanced depth imaging optical coherence tomography of choroidal metastasis in 14 eyes. Retina. 2014;34:1588–93.
pubmed: 24743640
doi: 10.1097/IAE.0000000000000131
Shields CL, Manalac J, Das C, Saktanasate J, Shields JA. Review of spectral domain enhanced depth imaging optical coherence tomography (EDI-OCT) of tumors of the choroid. Indian J Ophthalmol. 2015;63:117–21.
pubmed: 25827541
pmcid: 4399119
doi: 10.4103/0301-4738.154377
Shields CL, Manalac J, Das C, Saktanasate J, Shields JA. Review of spectral domain enhanced depth imaging optical coherence tomography (EDI-OCT) of tumors of the retina and retinal pigment epithelium in children and adults. Indian J Ophthalmol. 2015;63:128–32.
pubmed: 25827543
pmcid: 4399121
doi: 10.4103/0301-4738.154384
Shields JA, Shields CL, Ehya H, Eagle RC, Jr, DePotter P. Fine needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology. 1993;100:1677–84.
Shields CL, Manquez ME, Mashayekhi A, Danzig CJ, Ehya H, Shields JA. Fine needle aspiration biopsy of iris tumors in 100 consecutive cases. Tech complications Ophthalmol. 2006;113:2080–6.
Williams BK, Di Nicola M, Khoo CTL, Mashayekhi A, Ehya H, Shields JA, et al. Fine-needle aspiration biopsy of posterior segment intraocular tumors in 500 consecutive eyes. Submitted for publication.
Rudoler SB, Corn BW, Shields CL, DePotter P, Hyslop T, Shields JA, et al. External beam irradiation for choroid metastases: identification of factors predisposing to long-term sequelae. Int J Radiat Oncol Biol Phys. 1997;38:251–6.
pubmed: 9226310
doi: 10.1016/S0360-3016(97)00050-3
Rudoler SB, Shields CL, Corn BW, DePotter P, Hyslop T, Curran WJ, et al. Functional vision is improved in the majority of patients treated with external-beam radiotherapy for choroid metastases: a multivariate analysis of 188 patients. J Clin Oncol. 1997;15:1244–51.
pubmed: 9060569
doi: 10.1200/JCO.1997.15.3.1244
Shields CL, Shields JA, DePotter P, Quaranta M, Friere J, Brady LW, et al. Plaque radiotherapy for the management of uveal metastasis. Arch Ophthalmol. 1997;115:203–9.
pubmed: 9046255
doi: 10.1001/archopht.1997.01100150205010
Shields CL. Plaque radiotherapy for the management of uveal metastasis. Curr Opin Ophthalmol. 1998;9:31–7.
pubmed: 10182097
doi: 10.1097/00055735-199806000-00006
Kaliki S, Shields CL, Al-Dahmash SA, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis in 8 cases. Ophthalmology. 2012;119:1218–22.
pubmed: 22386261
doi: 10.1016/j.ophtha.2011.12.024
Shields CL, Khoo CTL, Mazloumi M, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis. Tumor control and visual outcomes in 58 cases. The 2019 Burnier International Ocular Pathology Society Lecture. Ophthalmol Ret 2020;4:310–319.
doi: 10.1016/j.oret.2019.10.009
Shields CL, Kancherla S, Patel J, Vijavargiya P, Suriano M, Kolbus E, et al. Clinical survey of 3680 iris tumors based on patient age at presentation. Ophthalmology. 2012;119:407–14.
pubmed: 22035581
doi: 10.1016/j.ophtha.2011.07.059
Shields CL, Shields PW, Manalac J, Jumroendararasame C, Shields JA. Review of cystic and solid tumors of the iris. Oman J Ophthalmol. 2013;6:159–64.
pubmed: 24379549
pmcid: 3872564
doi: 10.4103/0974-620X.122269
Shields JA, Shields CL, Kiratli H, De Potter P. Metastatic tumors to the iris in 40 patients. Am J Ophthalmol. 1995;119:422–30.
pubmed: 7709967
doi: 10.1016/S0002-9394(14)71227-9
Shields CL, Kaliki S, Crabtree GS, Peshtani A, Morton S, Anand RA, et al. Iris metastasis from systemic cancer in 104 patients: the 2014 Jerry A. Shields Lecture. Cornea. 2015;34:42–8.
pubmed: 25343701
doi: 10.1097/ICO.0000000000000285
Chen KJ, Chao AN, Wang CL. Iris metastasis regression following Osimertinib treatment. JAMA Ophthalmol. 2020;138:e202095. https://doi.org/10.1001/jamaophthalmol.2020.2095 .
doi: 10.1001/jamaophthalmol.2020.2095
pubmed: 33300967
Goduni L, Ashkenazy N, Hansen E, Soyano-Muller A, Correa ZM, Harbour JW. Iris metastasis from breast cancer successfully treated with Abemaciclib and Letrozole. Retin Cases Brief Rep. 2022. https://doi.org/10.1097/ICB.0000000000001176 .
Shields CL, McMahon JF, Atalay HT, Hasanreisoglu M, Shields JA. Retinal metastasis from systemic cancer in 8 cases. JAMA Ophthalmol. 2014;132:1303–8.
pubmed: 25033168
doi: 10.1001/jamaophthalmol.2014.2406
Whalen KE, Eagle RC Jr, Vrabec TR. A case of metastatic urothelial carcinoma of the retina and vitreous. Retin Cases Brief Rep. 2018;12:177–80.
pubmed: 27930437
doi: 10.1097/ICB.0000000000000490
Mano F, LoBue SA, Chang KC, Mano T. Multimodal imaging of retinal metastasis masquerading as an acute retinal necrosis. Int J Retin Vitreous. 2018;21:43. 4
doi: 10.1186/s40942-018-0149-4
Venkat A, Binkley EM, Srivastava S, Karthik N, Singh A. Immunotherapy-resistant vitreoretinal metastatic melanoma. Ocul Oncol Pathol. 2021;7:62–5.
pubmed: 33796519
doi: 10.1159/000511187
Shields JA, Shields CL, Singh AD. Metastatic neoplasms in the optic disc. The 1999 Bjerrum Lecture. Part 2. Arch Ophthalmol. 2000;118:217–24.
pubmed: 10676787
doi: 10.1001/archopht.118.2.217
Gündüz K, Shields JA, Shields CL, Eagle RC Jr. Cutaneous melanoma metastatic to the vitreous cavity. Ophthalmology. 1998;105:600–5.
pubmed: 9544631
doi: 10.1016/S0161-6420(98)94011-8
Kellermann N, Maier M, Feucht N. Vitreous metastasis of malignant cutaneous melanoma during treatment with ipilimumab. Ophthalmologe. 2017;114:163–6.
pubmed: 27260623
doi: 10.1007/s00347-016-0271-3
Francis J, Berry D, Abramson DH, Barkert CA, Bergstrom C, Demirci H, et al. Intravitreous cutaneous metastatic melanonma in the era of checkpoint inhibition. Ophthalmology. 2020;127:240–8.
pubmed: 31708274
doi: 10.1016/j.ophtha.2019.09.018
Gelman R, Lee SE, Rocha N, Kayserman LG, Vallar RV, Marr BP. Vitreous metastasis in a case of metastatic breast cancer. Ocul Oncol Pathol. 2020;6:323–7.
pubmed: 33123524
pmcid: 7574612
doi: 10.1159/000506949
Bowman CB, Guber D, Brown CH 3rd, Curtin VT. Cutaneous malignant melanoma with diffuse intraocular metastases. Arch Ophthalmol. 1994;112:1213–16.
pubmed: 8085965
doi: 10.1001/archopht.1994.01090210097022
Solomon JD, Shields CL, Shields JA, Eagle RC Jr. Posterior capsule opacity as initial manifestation of metastatic cutaneous melanoma. Graefes Arch Clin Exp Ophthalmol. 2011;249:127–31.
pubmed: 20617330
doi: 10.1007/s00417-010-1443-5
Paul SK, Chou L, Shields CL. Cutaneous melanoma metastatic to anterior lens capsule. JAMA Ophthalmol. 2018;136:e180095.
pubmed: 29522164
doi: 10.1001/jamaophthalmol.2018.0095
Quhill H, Mudhar HS, Cornish KS, Rennie IG. Cutaneous malignant melanoma metastasis to the pseudophakic lens capsule with associated granulomatous intraocular inflammation. Ocul Oncol Pathol. 2020;6:339–43.
pubmed: 33123527
pmcid: 7574621
doi: 10.1159/000507052
Glass AG, Lacey JV, Hoover RN. The rise in breast cancer incidence, 1960-2003 in Estrogen Receptor positive tumors. Proc Am Assoc Cancer Res. 2005;65:953–4.